Ortho Clinical Diagnostics, oo ah mid ka mid ah shirkadaha ogaanshaha fayraska ee ugu weyn adduunka, ayaa ku dhawaaqday bilaabista tijaabadii ugu horreysay ee COVID-19 IgG ee ka hortagga unugyada iyo baaritaan dhammaystiran oo COVID-19 nucleocapsid antibody ah.
Ortho waa shirkadda keliya ee Maraykanka ku taal oo bixisa isku-darka tijaabada tirada iyo tijaabinta nucleocapsid ee shaybaarada.Labadan baaritaanba waxay ka caawiyaan kooxda caafimaadka inay kala saaraan sababta unugyada difaaca jirka ee ka dhanka ah SARS-CoV-2 oo ay ka baaraandegaan nidaamka VITROS ee Ortho ee la aamini karo.
"Mareykanka, dhammaan tallaallada la tallaalay waxaa loogu talagalay inay soo saaraan jawaab-celin ka hortag ah oo ku aaddan borotiinka sare ee fayraska SARS-CoV-2," ayuu yiri Ivan Sargo, MD, Ortho Clinical Diagnostics, madaxa daawada, caafimaadka iyo arrimaha sayniska."Tijaabada cusub ee Ortho ee tirooyinka IgG antibody, oo ay weheliso baaritaankeeda cusub ee nucleocapsid antibody, ayaa bixin kara xog dheeri ah si loo go'aamiyo in jawaabta antibody-ku ay ka timaaddo infekshan dabiici ah ama tallaal borotiin ah oo lala beegsanayo."
Ortho's VITROS® Anti-SARS-CoV-2 IgG test antibody quantitative antibody waa tijaabadii ugu horeysay ee kahortaga unugyada gudaha Mareykanka si loo bixiyo qiyam lagu saleeyay sida waafaqsan heerarka caalamiga ah ee Ururka Caafimaadka Adduunka (WHO).2 Tijaabada antibody-ka ee la qiyaasey waxay caawisaa in la iswaafajiyo hababka serological SARS-CoV-2 waxayna ogolaataa isbarbardhigga xogta isku midka ah ee shaybaarada.Xogtan midaysan waa tillaabada ugu horreysa ee fahamka kor u kaca iyo hoos u dhaca unugyada difaaca jirka iyo saamaynta muddada fog ee cudurka COVID-19 uu ku leeyahay bulshada iyo guud ahaan dadka.
Tijaabada tirada cusub ee Ortho ee IgG waxaa loogu talagalay in lagu cabbiro unugyada difaaca jirka ee IgG ee ka dhanka ah SARS-CoV-2 ee serum iyo balaasmaha, oo leh 100% gaar ah iyo dareen aad u wanaagsan.3
Ortho's VITROS® Anti-SARS-CoV-2 Wadarta Nucleocapsid Antibody Test waa imtixaan 4 aad u sax ah oo lagu ogaanayo tayada SARS-CoV-2 nucleocapsid ee bukaanada uu ku dhacay fayraska SARS-CoV-2 Antibody.
"Waxaan si joogto ah u baranaynaa aqoon cusub oo ku saabsan fayraska SARS-CoV-2 maalin kasta, Ortho waxaa ka go'an in uu qalabeeyo shaybaarrada xalal sax ah oo sax ah si looga caawiyo inay la qabsadaan caqabadaha hadda iyo mustaqbalka ee cudurkan sii socda," ayuu yiri Dr. Chockalingam Palaniappan. , Madaxa Hal-abuurka ee Ortho Clinical Diagnostics.
Tijaabada ka hortagga tirada ee Ortho's COVID-19 waxay dhammaystirtay habka ogaysiinta isticmaalka degdega ah ee Maamulka Cunnada iyo Dawooyinka ee Maraykanka (EUN) May 19, 2021, waxayna u gudbisay oggolaanshaha isticmaalka degdega ah (EUA) ee tijaabada FDA.VITROS® Anti-SARS-CoV-2 wadarta guud ee tijaabinta ka hortagga unugyada nucleocapsid waxay dhammaysay nidaamka EUN Maajo 5, 2021, sidoo kale waxay gudbisay EUA.
Ma doonaysaa inaad si toos ah ugu soo dirto wararkii ugu dambeeyay ee sayniska sanduuqaaga?Noqo xubin SelectScience hadda bilaash >>
1. Bukaannada lagu tallaalay tallaallada fayraska aan dhaq-dhaqaaqin waxay soo saari doonaan unugyada-anti-N iyo anti-S.2. https://www.who.int/publications/m/item/WHO-BS-2020.2403 3. 100% gaar ah, 92.4% dareenka in ka badan 15 maalmood ka dib bilawga calaamadaha 4. 99.2% si gaar ah iyo 98.5% PPA ≥ 15 maalmood ka dib bilawga calaamadaha
Waqtiga boostada: Juun-22-2021